FDA accepts BLA for Priority Review of Opdivo + Yervoy in first-line NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has accepted supplemental Biologics License Application for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 
Advances such as new nontoxic, more effective immunotherapy and improvements that significantly reduce recovery times for complicated surgeries are making cancer treatments less taxing. On the horizon are more ways to give patients the greatest chance of survival while also reducing negative consequences of treatment. Some therapies also will improve the experience, such as chemotherapy consisting of quick subcutaneous injections instead of hours in an infusion chair. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login